leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics raises A$8.75 million to accelerate launch of products into global markets

The placement was strongly supported by new and existing sophisticated investors in Australia and the US and facilitated the entry of several new institutions from Australia onto the share register.

Zelira Therapeutics Ltd - Zelira Therapeutics raises A$8.75M to accelerate launch of products into global markets
Funds will be used to accelerate the launch of five products into global markets in 2020

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) placement of 175 million shares at A$0.05 per share has been strongly oversubscribed by new and existing investors, raising A$8.75 million.

Managed by Morgan’s Corporate Ltd, the placement received firm bids exceeding twice the intended amount and is set to increase the company’s cash position to around A$10.35 million, before costs.

Funds will be used to accelerate Zelira’s plans to launch multiple products into global markets and to advance its planned clinical programs.

“Delighted to welcome new investors”

Managing director Dr Richard Hopkins said: “The placement was strongly supported by existing and new investors both domestically and in the United States.

“We are delighted to welcome new sophisticated and institutional investors to our register and appreciate the ongoing support from our existing shareholders.

“We would also like to thank Morgans for completing the successful placement.”

Well-funded

The company is well-funded to leverage its unique ‘Launch, Learn and Develop’ model to launch products, generate revenues and progress development of clinically validated medicines.

Settlement is expected to occur on August 10 with the shares to be issued shortly thereafter.

Zelira Therapeutics is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest-growing cannabis markets.

The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

Zelira is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

Quick facts: Zelira Therapeutics Ltd

Price: 0.057 AUD

ASX:ZLD
Market: ASX
Market Cap: $65.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics with Proactive at ASX Small and Mid-Cap Conference

Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.  The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing...

1 week, 6 days ago

2 min read